Aclarion (NASDAQ:ACON – Get Free Report)‘s stock had its “hold” rating reaffirmed by investment analysts at Maxim Group in a research report issued on Friday,Benzinga reports.
Separately, Ascendiant Capital Markets dropped their price target on Aclarion from $1.50 to $1.30 and set a “buy” rating for the company in a research note on Wednesday, November 27th.
Read Our Latest Stock Analysis on ACON
Aclarion Price Performance
About Aclarion
Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
Featured Articles
- Five stocks we like better than Aclarion
- Insider Trades May Not Tell You What You Think
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Texas Instruments: The Old-School Tech Titan Still Delivering
- What does consumer price index measure?
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
